Artelo Biosciences Inc
ARTL1.470USD
+0.100+7.30%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
2.29MMarket Cap
LossP/E TTM
More Details of Artelo Biosciences Inc Company
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
Artelo Biosciences Inc Info
Ticker SymbolARTL
Company nameArtelo Biosciences Inc
IPO dateOct 13, 2015
CEOGorgas (Gregory D)
Number of employees6
Security typeOrdinary Share
Fiscal year-endOct 13
Address505 Lomas Santa Fe, Suite 160
CitySOLANA BEACH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92075
Phone18589257049
Websitehttps://artelobio.com/
Ticker SymbolARTL
IPO dateOct 13, 2015
CEOGorgas (Gregory D)
Company Executives of Artelo Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Gregory D. (Greg) Gorgas
Mr. Gregory D. (Greg) Gorgas
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
3.41K
--
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairperson of the Board
Independent Chairperson of the Board
630.00
--
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
Independent Director
Independent Director
139.00
--
Dr. Douglas Blayney, M.D.
Dr. Douglas Blayney, M.D.
Independent Director
Independent Director
--
--
Dr. R. Martin Emanuele, Ph.D.
Dr. R. Martin Emanuele, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gregory R. Reyes, M.D., Ph.D.
Dr. Gregory R. Reyes, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Director
Independent Director
--
--
Mr. Mark E. Spring, CPA
Mr. Mark E. Spring, CPA
Chief Financial Officer, Treasurer, Principal Financial Officer, Principal Accounting Officer
Chief Financial Officer, Treasurer, Principal Financial Officer, Principal Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Gregory D. (Greg) Gorgas
Mr. Gregory D. (Greg) Gorgas
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
3.41K
--
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairperson of the Board
Independent Chairperson of the Board
630.00
--
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
Independent Director
Independent Director
139.00
--
Dr. Douglas Blayney, M.D.
Dr. Douglas Blayney, M.D.
Independent Director
Independent Director
--
--
Dr. R. Martin Emanuele, Ph.D.
Dr. R. Martin Emanuele, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gregory R. Reyes, M.D., Ph.D.
Dr. Gregory R. Reyes, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Feb 1
Updated: Sun, Feb 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
UBS Financial Services, Inc.
1.66%
DRW Securities, LLC
0.85%
The Vanguard Group, Inc.
0.69%
Farb (Daniel Stuart)
0.25%
Gorgas (Gregory D)
0.17%
Other
96.37%
Shareholders
Shareholders
Proportion
UBS Financial Services, Inc.
1.66%
DRW Securities, LLC
0.85%
The Vanguard Group, Inc.
0.69%
Farb (Daniel Stuart)
0.25%
Gorgas (Gregory D)
0.17%
Other
96.37%
Shareholder Types
Shareholders
Proportion
Investment Advisor
3.21%
Individual Investor
0.47%
Research Firm
0.08%
Other
96.24%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
17
33.04K
1.41%
--
2025Q3
20
33.04K
2.15%
+11.84K
2025Q2
19
16.59K
3.27%
+2.16K
2025Q1
19
14.43K
2.63%
+32.00
2024Q4
19
5.75K
4.25%
+1.99K
2024Q3
20
3.76K
4.35%
-524.00
2024Q2
28
4.29K
5.29%
+147.00
2024Q1
27
4.14K
5.67%
-26.34K
2023Q4
34
4.28K
6.32%
-4.63K
2023Q3
35
8.91K
11.01%
+2.12K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
UBS Financial Services, Inc.
126.00
0.01%
+37.00
+41.57%
Sep 30, 2025
DRW Securities, LLC
17.18K
0.85%
+17.18K
--
Sep 30, 2025
The Vanguard Group, Inc.
14.03K
0.69%
+9.42K
+204.16%
Sep 30, 2025
Farb (Daniel Stuart)
5.10K
0.25%
-147.90K
-96.67%
Oct 20, 2025
Gorgas (Gregory D)
3.41K
0.17%
--
--
Dec 10, 2025
Morgan Stanley & Co. LLC
1.10K
0.05%
+1.10K
--
Sep 30, 2025
Matsui (Connie L)
630.00
0.03%
--
--
Dec 10, 2025
Citi Investment Research (US)
477.00
0.02%
+468.00
+5200.00%
Sep 30, 2025
Blayney (Douglas W)
139.00
0.01%
--
--
Dec 10, 2025
Kelly (Steven)
139.00
0.01%
--
--
Dec 10, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jun 11, 2025
Merger
6→1
Aug 09, 2022
Merger
15→1
Aug 09, 2022
Merger
15→1
Aug 09, 2022
Merger
15→1
Aug 09, 2022
Merger
15→1
Date
Ex-dividend Date
Type
Ratio
Jun 11, 2025
Merger
6→1
Aug 09, 2022
Merger
15→1
Aug 09, 2022
Merger
15→1
Aug 09, 2022
Merger
15→1
Aug 09, 2022
Merger
15→1
